Skip to content
value.today

Adial Pharmaceuticals, Inc.

ADIL
$69 Mmarket cap on Oct 30, 2026+3336.0% since Jan 2024
Compare
World rank
#20,152
Revenue
—
For year ending December-2022
Net income
$-13 M
SEC filing
Employees
—

Adial Pharmaceuticals, Inc. in brief

Adial Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Encino, California, USA. Its market value was $69 M on 30 October 2026, which makes it the 20,152nd largest listed company in the world and the 3,720th largest in the USA on this site. Matt Davidson is its chief executive. Its shares trade under the symbol ADIL (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Adial Pharmaceuticals, Inc.

We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Our investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. AD04 was investigated in a Phase 3 clinical trial, designated the ONWARD trial, for the potential treatment of AUD in subjects with certain target genotypes, which were identified using our companion diagnostic genetic test. Based on our analysis of the subgroup data from the ONWARD trial, we are now focused on completing the clinical development program for AD04 in the specified genetic subgroups to meet regulatory requirements primarily in the US and secondarily in Europe/UK.

From the company's annual report filed with the US SEC: read the report

Adial Pharmaceuticals, Inc. timeline

4 events, 2011–2026
  1. 2011
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2017
  4. ✎
    Renamed Adial Pharmaceuticals, Inc.
    Formerly ADial Pharmaceuticals, L.L.C..
  5. 2018
  6. 🔔
    Initial public offering as Adial Pharmaceuticals, Inc.
    Final prospectus filed with the SEC on 30 July 2018; shares registered for exchange trading on 23 July 2018.
  7. 2026
  8. ✎
    Renamed Azora Therapeutics, Inc. (DE)
    Formerly Adial Pharmaceuticals, Inc..

Events of Adial Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$19 M$37 M$56 M$74 M2020202120222023202420252026

World rank over time

▲ up 4,128 places since 2020
2020-01-01: #24326#24,32620202021-01-01: #22808#22,80820212022-01-07: #26376#26,37620222022-12-25: #32443#32,44320222023-07-30: #32212#32,21220232024-01-05: #33363#33,36320242026-03-08: #13544#13,54420262026-08-01: #22947#22,94720262026-10-14: #21567#21,56720262026-10-30: #20198#20,1982026

Rank in USA: #4,413 (Jan 2020) · #4,352 (Jan 2021) · #4,863 (Jan 2022) · #5,721 (Dec 2022) · #5,498 (Jul 2023) · #4,726 (Jan 2024) · #2,486 (Mar 2026) · #4,048 (Aug 2026) · #3,866 (Oct 2026) · #3,724 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
13.0×
Free cash flow yield
-17.5%
Net margin
—
Operating margin
—
Return on equity
-241.1%
Liabilities / assets
21.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue —, net income $-1M—FY17Fiscal year ending Dec 2018: revenue —, net income $-12M—FY18Fiscal year ending Dec 2019: revenue —, net income $-9M—FY19Fiscal year ending Dec 2020: revenue —, net income $-11M—FY20Fiscal year ending Dec 2021: revenue —, net income $-19M—FY21Fiscal year ending Dec 2022: revenue —, net income $-13M—FY22
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2022——$-11M$-13M—
Dec 2021——$-19M$-19M—
Dec 2020——$-11M$-11M—
Dec 2019——$-8M$-9M—
Dec 2018——$-7M$-12M—
Dec 2017——$-1M$-1M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2022$-11M——$-12.71—
Dec 2021$-12M$0M$-12M$-1.04—
Dec 2020$-8M——$-0.87—
Dec 2019$-6M——$-0.87—
Dec 2018$-3M——$-2.44—
Dec 2017$-0M——$-0.35—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-2M—Dec ’24Three months to Mar 2025: revenue —, net income $-2M—Mar ’25Three months to Jun 2025: revenue —, net income $-2M—Jun ’25Three months to Sep 2025: revenue —, net income $-2M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-2M—Dec ’25Three months to Mar 2026: revenue —, net income $-2M—Mar ’26Three months to Jun 2026: revenue —, net income $-52M—Jun ’26Three months to Sep 2026: revenue —, net income $-65M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-65M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of Adial Pharmaceuticals, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-11 M
Net income
$-13 M

For year ending December-2022 · source: SEC filing

Balance sheet

Total assets
$7 M
Total liabilities
$1 M
Total equity
$5 M

As of December-2025

Top 22 institutional investors in Adial Pharmaceuticals, Inc.#

As of Sep 30, 2026
22 institutions held 700,246 shares (about 4.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 4.9%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 22 largest institutional investors in Adial Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1KVP Capital Advisors, LP210,256New1.47%$1 MNov 16, 2026
2Diadema Partners LP181,890New1.27%$1 MNov 16, 2026
3Acuta Capital Partners, LLC129,982New0.91%$1 MNov 16, 2026
4Jane Street Group, LLC53,952+21,833 (+67.98%)0.38%$0 MNov 12, 2026
5Citadel Advisors LLC29,753+206 (+0.70%)0.21%$0 MNov 16, 2026
6XTX Topco Ltd26,771New0.19%$0 MNov 16, 2026
7Geode Capital Management, LLC21,546+9,153 (+73.86%)0.15%$0 MNov 6, 2026
8Vanguard Fiduciary Trust Co15,879+10,000 (+170.10%)0.11%$0 MNov 13, 2026
9China Universal Asset Management Co., Ltd.12,800+4,800 (+60.00%)0.09%$0 MOct 28, 2026
10Vanguard Capital Management LLC10,407+4,576 (+78.48%)0.07%$0 MNov 13, 2026
11Manchester Capital Management LLC1,9230 (0.00%)0.01%$0 MOct 22, 2026
12Tower Research Capital LLC (TRC)1,777+358 (+25.23%)0.01%$0 MNov 16, 2026
13UBS Group AG1,688-17,459 (-91.18%)0.01%$0 MNov 10, 2026
14Barclays PLC1,094New0.01%$0 MNov 6, 2026
15BlackRock, Inc.3040 (0.00%)0.00%$0 MNov 13, 2026
16Raffa Wealth Management, LLC830 (0.00%)0.00%$0 MNov 16, 2026
17Morgan Stanley500 (0.00%)0.00%$0 MNov 13, 2026
18SBI Securities Co., Ltd.45-2 (-4.26%)0.00%$0 MOct 22, 2026
19Northwestern Mutual Wealth Management Co30New0.00%$0 MNov 13, 2026
20Caitong International Asset Management Co., Ltd9New0.00%$0 MOct 29, 2026
21Wells Fargo & Company/mn60 (0.00%)0.00%$0 MNov 16, 2026
22Abound Wealth Management10 (0.00%)0.00%$0 MOct 26, 2026

Mutual funds holding Adial Pharmaceuticals, Inc.#

3 funds hold shares worth $0 M (about 0.2% of the company). Since their previous reports 1 added shares and 1 sold, buying $0 M net.
Mutual funds holding Adial Pharmaceuticals, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC23,596$0 M0.17%<0.01%+347%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.361$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC310$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Adial Pharmaceuticals, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$106 K
5 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$106 K
open market only
Insiders on file
13
since
$65 K$0Jun 2026: bought $65 K (1 trades), sold $0 (0 trades)Jun 26Jul 2026: bought $41 K (4 trades), sold $0 (0 trades)Jul
Bought (open market)Sold (open market)Hover a month for the totals
Adial Pharmaceuticals, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Julie SaikiChief Strategy OfficerConversion+626,252——761,636Form 4
filed Matt DavidsonPresident and CEO, DirectorConversion+524,954——819,018Form 4
filed Matt DavidsonPresident and CEO, DirectorConversionindirect+101,298——104,725Form 4
filed Matt DavidsonPresident and CEO, DirectorGrant or award+232,417——294,064Form 4
filed Coastlands Capital LP10% ownerBuyindirect+1,233$2.750$3 K388,308Form 4
filed Coastlands Capital LP10% ownerBuyindirect+2,000$2.650$5 K387,075Form 4
filed Coastlands Capital LP10% ownerBuyindirect+1,700$2.700$5 K385,075Form 4
filed Coastlands Capital LP10% ownerBuyindirect+10,053$2.790$28 K383,375Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Adial Pharmaceuticals, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
217,174
19.5% of shares · 4.13 days to cover
Buybacks, Q4 2023
$0M
Q4 2023
Shares sold short, last 24 reportsAll stocks →
Adial Pharmaceuticals, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2023Q4 2023$0M

Trading halts

  • 2026-11-02 14:40 UTC, code LUDP, resumed 14:45 UTC
  • 2026-11-02 14:31 UTC, code LUDP, resumed 14:36 UTC
  • 2026-06-11 16:43 UTC, code LUDP, resumed 16:48 UTC
  • 2026-06-11 15:44 UTC, code LUDP, resumed 16:26 UTC
  • 2026-02-06 00:50 UTC, code T3, resumed 14:00 UTC

Fails to deliver

  • : 8,170 shares at $4.81
  • : 25,052 shares at $0.01
  • : 192 shares at $3.92
  • : 986 shares at $4.11
  • : 485 shares at $3.51

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Adial Pharmaceuticals, Inc. scorecard#

Passes 1 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median13.0×Price to book 13.0× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-17.5%Free cash flow is -17.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-11.93 vs -68.01Diluted EPS -11.93 in fiscal 2025 against -68.01 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitabilitynot known
    • –Profitable in the newest yearNo net income on file.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities4.4×Current ratio 4.41 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year244.8%Diluted shares up 244.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Adial Pharmaceuticals, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Adial Pharmaceuticals, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017
Income statement
Research and development2,6203,2291,2671,950r8,3965,8533,966368182
General and administrative5,1805,0555,6218,909r9,3455,0754,2796,619813
Operating expenses7,7998,2846,88810,859r19,28910,9288,2456,987995
Total costs and expenses———550—————
Operating income−7,799−8,284−6,888−10,859r−19,289−10,928−8,245−6,987−995
Interest and finance income1501797063r6.532957.40.4
Share of profit of associates−492−552−194——————
Other non-operating income (expense)−178−4,913−11463r−22935−347−4,644−144
Income before tax−7,977−13,197−7,002−10,796r−19,517−10,893−8,591−11,631−1,139
Income tax———−0.5−94————
Income from continuing operations—−13,197−7,002−10,796—————
Income from discontinued operations——1,879−1,935—————
Net income including minority interests————−19,423−10,893−8,591——
Net income attributable to shareholders−7,977−13,197−5,123−12,731−19,423−10,893−8,591−11,631−1,139
Earnings per share, basic-11.93-68.01r-3.60-12.71r-1.04-0.87-0.87-2.44-0.35
Earnings per share, diluted-11.93-68.01r-3.60-12.71r-1.04-0.87-0.87-2.44-0.35
Shares, weighted average (basic)0.70.2—2519————
Shares, weighted average (diluted)0.70.2r1.41.0r19129.90.20.2
Balance sheet
Cash and cash equivalents5,8813,7512,8274,0026,0624,4016,7773,86918
Other current assets300r3083723493905023593189.0
Current assets6,181r4,0593,1994,7806,4625,1367,6734,69327
Property, plant and equipment———5058————
Right-of-use (leased) assets———194246————
Goodwill———249249————
Other intangible assets3.0r3.33.94.55.05.66.26.77.3
Investments in associates490r9821,534——————
Total assets6,674r5,0444,7375,7337,4755,4917,6804,69935
Accounts payable655r250103276r286649190100r342
Current liabilities1,397r9766531,7912,7221,5055392581,032
Lease liabilities (non-current)———151207————
Total liabilities1,397r9766532,4563,9671,505———
Retained earnings−89,972r−81,995−68,798−63,675−50,943−31,520−20,627−12,035−404
Shareholders' equity5,277r4,068r4,0843,2763,5083,9867,1414,441−998
Total liabilities and equity6,674r5,0444,7375,7337,4755,4917,6804,69935
Shares outstanding1.10.3r1.71.1r2114106.93.3
Cash-flow statement
Share-based compensation6767971,7463,3744,2402,0141,6025,368205
Cash from operating activities−6,493−6,922−6,807−11,186−11,949−7,633−6,339−2,498−495
Capital expenditure————−65————
Acquisitions, net of cash acquired————−31————
Cash from investing activities150—1,500—−34−350——35
Shares issued3,6594,0217509,12411,7505,157———
Shares bought back——−1.7——————
Cash from financing activities8,4737,8464,1329,12613,6455,6079,2476,349390
Change in cash—————−2,3762,9083,851−70
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Adial Pharmaceuticals, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$891 K
Cary Claiborne
Other top executives, average
$464 K
the CEO earned 1.9× this
$100 invested is now
$4
Adial Pharmaceuticals, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Cary Claiborne$891 K$600 K$464 K$4
2024Matt Davidson$976 K$824 K$352 K$19
2023Matt Davidson$802 K$576 K$412 K$35

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Adial Pharmaceuticals, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Acquisition or sale completed 1 · Directors and officers 8 · Material agreement 5 · Agreement ended 1 · New debt 1 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 4 · Shareholder vote 3 · Results announced 6

Adial Pharmaceuticals, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Directors and officersShareholder vote8-K
Material agreement8-K
Unregistered share sale8-K
Delisting notice8-K
Results announced8-K
Directors and officers8-K
Acquisition or sale completedDirectors and officersMaterial agreementNew debtUnregistered share saleBylaws or fiscal year changed8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Material agreementAgreement ended8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Adial Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2025$4 MPrivate placement after listing$2 to $10 million1optionsSEC
May 2025$5 MPrivate placement after listing$2 to $10 million1optionsSEC
Oct 2023$4 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Feb 2022$10 MPrivate placement after listing$10 to $50 million1optionsSEC
Jun 2020$5 MPrivate placement after listing$2 to $10 million6equity, optionsSEC
Jun 2013$3 MNo. 2$2 to $10 million35equitySEC
Mar 2011$4 MNo. 1$2 to $10 million—equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Adial Pharmaceuticals, Inc.#

$40 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.

Lobbying, 2025
$40 K
#1,394 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$20 K
  • Health Issues4 reports

Lobbying firms hired in 2025

RK STRATEGIES, INC. $40 K

Adial Pharmaceuticals, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$20 K—2
2025$40 K—4
2024$10 K—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Adial Pharmaceuticals, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Adial Pharmaceuticals, Inc. compares in Biotechnology

  • Market cap$69 M · higher than 30% of 726
  • Price / book13.0× · lower than 12% of 534
  • FCF yield-17.5% · higher than 46% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Adial Pharmaceuticals, Inc.🇺🇸$69 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2022
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Adial Pharmaceuticals, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Adial Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Adial Pharmaceuticals, Inc.? Suggest a correction